Skip to main content
. Author manuscript; available in PMC: 2022 Mar 15.
Published in final edited form as: Cancer Discov. 2022 Mar 1;12(3):712–729. doi: 10.1158/2159-8290.CD-20-0930

Figure 7. Efficacy of combined dasatinib and trametinib on ex vivo brain slice preparations.

Figure 7

(A) Coronal slices of normal mouse brain, counterstained with Hoechst33342 (aqua) are implanted in the pontine region with ICR-B169 parental cells, stained with human nuclear antigen (orange), and treated for 4 days with 1μM dasatinib, 0.1234μM trametinib, or both, compared to vehicle control. Scale bar is 2 mm. (B) Barplot of quantification of tumour cell infiltration across the brain parenchymal tissue as measured by the calculated area invaded compared to vehicle control. Plotted is the mean of at least 6 independent slices, error bars represent the standard deviation. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, FDR-corrected t-test.